Incidence of PTLD in Pediatric Renal Transplant Recipients Receiving Basiliximab, Calcineurin Inhibitor, Sirolimus and Steroids
05/2008
Journal Article
Authors:
McDonald, R.;
Smith, J.;
Ho, M.;
Lindblad, R.;
Ikle, D.;
Grimm, P.;
Wyatt, R.;
Arar, M.;
Liereman, D.;
Bridges, N.;
Harmon, W.;
Group, C.C.T.P.T.Study
Secondary:
Am J Transplant
Volume:
8
Pagination:
984-989
URL:
http://www.ncbi.nlm.nih.gov/pubmed/18416737
Keywords:
Adolescent; Adrenal Cortex Hormones; Adult; Antibodies-Monoclonal; Child; Cyclosporine; Double-Blind Method; Female; Immunosuppressive Agents; Infant; kidney transplantation; Lymphoproliferative Disorders; Multivariate Analysis; Postoperative Complication
Abstract:
{Pediatric renal transplant recipients were enrolled in a multicenter, randomized, double-blind trial of steroid withdrawal. Subjects received basiliximab, calcineurin inhibitor, sirolimus and steroids. Of 274 subjects enrolled, 19 (6.9%) subjects developed posttransplant lymphoproliferative disorder (PTLD). The relative hazard (RH) for PTLD was 5.3-fold higher in children aged < or =5 versus those >12 years (p = 0.0017). EBV seronegative subjects had a 4.7-fold higher RH compared to EBV positive subjects (p = 0.02). Among EBV donor+/recipient- (D+/R-) subjects, the RH increased by 6.1-fold (p = 0.0001). In a multivariate model, risk factors included recipient age < or =5 years (RH 3.2, 95% CI: 1.1-9.6
